Company
Radiopharm Theranostics Ltd
ASX:RAD
Radiopharm Theranostics is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals. The company is advancing a pipeline of distinct radiopharmaceutical technologies for novel oncology targets—avoiding "me-too" targets like Prostate-Specific Membrane Antigen (PSMA), Fibroblast Activation Protein (FAP) or Somatostatin Receptor 2 (SSTR2).
101 stories · page 1 of 2
Radiopharm Theranostics advances clinical trials towards multiple inflection points
RAD's radiopharmaceutical assets – already in advanced clinical trials – have unlimited potential because they can be used instead of or in combination with other cancer treatments. They also have a role in diagnosis.
Radiopharm Theranostics rounds out entitlement offer with $1.2 million retail raise
The retail component brings RAD’s near $10 million entitlement offer to a close, with the institutional raise bringing A$5.5 million to the table.
Radiopharm Theranostics reaches agreement with ANSTO for supply of key isotope lutetium-177
The isotope will be used for the company's Phase I therapeutic trial in patients with non-small cell lung cancer.
Radiopharm Theranostics secures second supply of Actinium-225 from NorthStar Medical Radioisotopes
“It remains a priority for us to secure these key supply agreements, which allow us to continue with our clinical development unimpeded,” said RAD CEO and MD Riccardo Canevari.
Radiopharm Theranostics off to strong start in $10 million raise with institutional offer bringing in $5.5 million
“We are thrilled to have delivered a positive Phase 2 trial readout in brain mets which has a significant unmet clinical need just 11 months since IPO,” Radiopharm executive chairman Paul Hopper said.
Radiopharm Theranostics launches entitlement offer to raise up to $10 million
The company expects that the offer will provide a runway until at least the end of 2023, including for F 18 Pivalate PET that has returned positive Phase 2 data.
FIVE at FIVE AU: Rio to unlock giant ore body; China delays GDP figures; rental crisis hits inflation
The Reserve Bank of Australia has said that Australia's rental crisis is contributing to high inflation.
Radiopharm Theranostics welcomes positive Phase 2 data for F-18 Pivalate in brain metastases trial
Radiopharm has an exclusive worldwide licence for the Pivalate platform technology from Cancer Research Technology Limited and Imperial College London.
Radiopharm Theranostics welcomes proof of concept for LRRC15 tumour targeting from prestigious scientific journal publication
The company says the publication of this evidence in Nature strengthens its already robust assessment of LRRC15 as a biomarker for aggressive malignancies, which it will follow up with a clinical trial assessing DUNP15's effect on the prote
Radiopharm Theranostics has Ga68-Integrin (RAD301) selected for presentation at European Association of Nuclear Medicine congress
“It is a pleasure to see the excellent work of the medical team from Dresden receive this recognition by the EANM committee for their first translation of TRIMT´s Trivehexin (RAD301) in the clinical setup,” said RAD CEO and MD Riccardo Cane
Radiopharm Theranostics to present interim data and continues to validate work with brain cancer
“We are very pleased to see a new molecule and an innovative mode of action in an area of high unmet medical need and we cannot wait to see the data presented,” Radiopharm’s CEO and managing director Riccardo Canevari.
Radiopharm Theranostics enters supply agreement to strengthen clinical pipeline of radiopharmaceutical products
“We are excited that our isotopes will play a critical role in Radiopharm Theranostics’ programs that aim to revolutionise cancer treatment,” SHINE’s Therapeutics Division general manager Chris Vessell said.
Radiopharm Theranostics shares surge after securing FDA's rare paediatric disease designation for DUNP19 technology
Radiopharm signed an exclusive licensing agreement with University of California Los Angeles (UCLA) for the promising LRRC15 antibody DUNP19 in April 2022.
Radiopharm Theranostics and MD Anderson launch joint venture to develop novel radiopharmaceuticals
The new entity formed by the medtech and the university will bring together product development expertise and clinical innovation.
Radiopharm Theranostics secures orphan drug designation for DUNP19 osteosarcoma treatment
“The resulting benefits of orphan designation will allow us to continue the development work of DUNP19’s inventor Dr David Ulmert with an even greater level of confidence," CEO and MD Riccardo Canevari said.
Radiopharm Theranostics’ key partnerships aiding progress in clinical trials: Diamond Equity Research
The NYC-based global equity research firm has valued Radiopharm at A$0.88 per share, an implied upside of more than four-fold from Radiopharm’s current share price of A$0.21
Radiopharm Theranostics inks Lantheus strategic collaboration; secures NM-01 licensing agreement with Nanomab
“We look forward to seeing the results of the Phase 2 PD-L1 imaging trial and to continuing our relationship with Lantheus into the future,” CEO and MD Riccardo Canevari said.
Radiopharm Theranostics extends agreement for Australian prostate cancer trial with GenesisCare
“GenesisCare is a leader in cancer care and to further the relationship with the company adds to our confidence as we move through the various steps in our clinical development,” CEO and MD Riccardo Canevari said.
Radiopharm Theranostics’ next-generation imaging data presented at Sixth World Theranostics Conference
The results concluded that Ga-68-Trivehexin is a promising non-invasive molecular imaging agent for certain head, neck and pancreatic tumours, with the potential to replace 18F-FDG as the standard-of-care radiotracer.
Radiopharm Theranostics strengthens Scientific Advisory Board with highly credentialed professor
“Susann [Brady-Kalnay] brings to the Scientific Advisory Board another excellent knowledge base and degree of experience in the molecular theranostic field," Radiopharm Theranostics managing director and CEO Riccardo Canevari said.
Radiopharm Theranostics signs new agreement to accelerate asset development
The agreement supplies RAD Lutetium-177 NCA, a key isotope required for multiple clinical trials in RAD's clinical pipeline, and thus the ability to accelerate several assets.
Radiopharm Theranostics secures brain tumour-targeting technology for clinical pipeline portfolio
“A number of tumour types can be detected with this novel PTPµ-targeted agent. Due to the limited treatment options and immediate need for therapies, we are focused on detecting and treating aggressive brain tumours with the PTPµ-targeted a
Radiopharm Theranostics appoints ex big pharma leader to board
Dr Leila Alland has a wealth of experience including leadership roles at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to multiple successful drug approvals.
Radiopharm Theranostics appoints highly experienced COO
“Having known Vittorio from our previous experiences in the sector and with AAA, I’m very confident in the expertise and capability he will bring to Radiopharm,” Radiopharm CEO and managing director Riccardo Canevari says.
Radiopharm Theranostics’ AVβ6-Integrin platform gains recognition in Europe as it continues clinical progress
AVβ6 offers noteworthy performance for radiolabelling and is a promising candidate for the early detection of challenging cancers such as pancreatic and head & neck cancer by PET imaging.
Radiopharm Theranostics’ transformative acquisition and progress in clinical trials to drive value: Diamond Equity Research
Diamond Equity Research updated its valuation for Radiopharm following the signing of an exclusive antibody licensing agreement with the University of California Los Angeles (UCLA).
Radiopharm licenses dual action monoclonal antibody targeting LRRC15 expression
“DUNP19 has demonstrated promise for several indications, but its potential as first in class therapy for osteosarcoma is particularly exciting, considering the high unmet need in the children and adolescents who typically suffer this disea
Radiopharm Theranostics signs LOI with Australia’s largest provider of integrated cancer care
“We are proud to have entered an LOI with GenesisCare, Australia’s largest provider of integrated cancer care, to support a trial for our innovative radiopharmaceutical therapy targeting non-small cell lung cancer, pending ethics approval f
Radiopharm Theranostics beefs up executive team ahead of roadshow and steams ahead with pipeline development
The company is planning face-to-face meetings as part of an upcoming roadshow to update investors on its progress.
Radiopharm Theranostics inks supply agreement for Actinium-225 with Terrapower for next-gen cancer treatments
The supply agreement is for an initial period of three years and may be extended for a further two successive 12-month periods.
Radiopharm Theranostics attracts $0.84 share price valuation from Diamond Equity Research
“There is tremendous growth projected for radiopharmaceutical therapies over the next five to 10 years, when you can combine the right molecule with the right isotope in areas of high unmet medical need,” said CEO Riccardo Canevari.
Radiopharm Theranostics accelerates pancreatic cancer clinical development in the US; releases isotope supply agreement details
It has been a busy time for the company, with plans advancing for the clinical development of a pancreatic cancer treatment in the US, and the sealing of an isotope supply deal with TerraPower.
Radiopharm Theranostics targets rapid growth with appointment of Hester Larkin as director
Larkin will bring big pharma and nuclear medicine expertise, as well as corporate leadership know-how, to the non-executive role.
Radiopharm Theranostics partners with nuclear innovation company on next gen cancer treatments
The company, through nuclear company TerraPower, has harnessed the rare medical isotope Actinium-225 for use in its radiopharmaceutical therapies for cancer.
Radiopharm Theranostics acquires IP for three cancer-fighting nanobodies targeting solid tumours
The company adds the intellectual property for the cancer-fighting nanobodies to its stable of cancer diagnosis and treatment assets.
Radiopharm Theranostics initiated by Diamond Equity Research with a valuation of 84 cents
Radiopharm has licensed a diversified pipeline of Radiopharmaceutical Therapies (RPTs) spanning from peptides, humanized monoclonal antibodies, and small molecules addressing roughly 75% of the causes of death from cancer.
Radiopharm Theranostics enhances management team skillset with three key appointments
“The new appointments complement the team of industry experts assembled by RAD this year as it continues to test its portfolio of licensed assets that include peptides, small molecules and monoclonal antibodies,” says MD.
Radiopharm Theranostics completes Phase 1 breast cancer imaging study in Shanghai
The Phase 1 trial of 40 patients in Shanghai propels the company towards confirming its asset, RAD201, as a useful diagnostic tool in breast cancer.
Radiopharm Theranostics' diversified portfolio of cancer treatments sees it make promising debut: Independent Investment Research
The broker has assigned RAD a value of $0.86 per share – $0.76 per share on a fully diluted basis – which accounts for the strongest assets in the company’s pipeline, including five candidates across a range of cancer indications.
Radiopharm Theranostics integrin platform technology features in prestigious 'Cancers' research journal
The article concluded that of all integrins, avβ6, the variety used by Radiopharm, is "arguably the most promising target structure for radiotheranostics," recognising its broad clinical scope across oncology as well as fibrotic diseases, w
Radiopharm Theranostics appoints Dr Sara Hurvits to scientific advisory board
“We are thrilled to have Dr Hurvitz join our highly experienced scientific advisory board,” says Radiopharm CEO and managing director.
Radiopharm Theranostics hits the ASX after $50 million IPO
As the latest company to hit the local share market, RAD is prepared to advance its radiopharmaceutical pipeline and develop solutions for the diagnostic and therapeutic spheres.
Radar Iron to discuss the road to iron ore feasibility studies at upcoming One2One Forum in Sydney
Want to ask CEO's probing questions? Proactive Investors provides the forum. Next up in Sydney is Radar Iron, Norwest Energy, ZYL Limited, Latin Resources, and Northwest Resources.
Sheffield Resources, Radar Iron, Kidman Resources, Fortis Mining, Glory Resources gain in IPO review
With 19 resource IPO's hitting the ASX boards around one year ago - Proactive Investors Australia are here to provide a performance review over the turbulent 2011. Find out which companies investors are supporting, and selling.
Radar Iron identifies DSO iron ore targets at Jackson and Boondine projects
The news flow is about to ramp up for Radar's assets in the Yilgarn Iron Ore Province, with the drilling of up to 20 DSO targets at Johnston Range commencing in October, and a maiden JORC Resource from Die Hardy expected in November.